Vanguard disaggregates holdings after realignment; KRYS shows 0% ownership (KRYS)
Rhea-AI Filing Summary
Krystal Biotech Inc filing shows an amended Schedule 13G/A by The Vanguard Group reporting 0 shares and 0% beneficial ownership as of the filing; the amendment documents an internal realignment effective January 12, 2026 that disaggregated certain Vanguard subsidiaries for SEC reporting. The form is signed on 03/27/2026.
Positive
- None.
Negative
- None.
Insights
Vanguard reports no beneficial stake in KRYS after internal realignment.
The amendment states 0 shares and 0% beneficial ownership as reported on 03/27/2026. It also records an internal reorganization dated January 12, 2026 that caused previously aggregated holdings to be reported separately by subsidiaries.
This filing clarifies reporting structure rather than indicating active buying or selling; subsequent filings from Vanguard subsidiaries may show holdings if tied to the realignment.
Amendment cites SEC Release No. 34-39538 to justify disaggregated reporting.
The disclosure references January 12, 1998 SEC Release No. 34-39538 and explains that certain subsidiaries will report beneficial ownership separately after Vanguard's internal realignment on January 12, 2026. The filing affirms that Vanguard no longer is deemed to beneficially own securities held by those subsidiaries.
Signatures show the form was executed on 03/27/2026; future Schedule 13 filings from related Vanguard entities could reflect any holdings.
AI-generated analysis. How Rhea-AI works. Not financial advice.